METTL3 is upregulated in both GC and CRC, and the elevation in METTL3 is a prognostic factor for poor overall survival (OS) and disease-free survival (DFS) (Li et al., 2019; Yue et al., 2019; Wang et al., 2020d). Here, METTL3 is linked to colorectal carcinoma.